The Lp(a) Letdown and Tumors After Gene Therapy

Friday, November 13, 2026

In today's episode, Dr. Jennifer Lincoln (@drjenniferlincoln) & Eva Johnson cover two large heart drug trials that lowered markers but not events. They break down Lp(a)HORIZON, which tested pelacarsen, and ZEUS, which tested ziltivekimab. They explain why moving a risk marker is not the same as changing outcomes. Plus: they also discuss an FDA investigation into tumors after the SMA gene therapy Zolgensma, what monitoring may mean for practice, an NFL star's scary neck injury, and more.

New to Medlines? Check out the full playlist: https://www.youtube.com/playlist?list=PLR-tmjMS1yRo

Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit https://www.medlinespod.com or email medlines@human-content.com.

Sources & Media Attributions for Today's Episode Available At: https://www.medlinespod.com/sources

Medlines is a Human Content Production